Clinical Trial Results:
An Open-Label, Long-Term Safety Study of A Long-acting Human Growth Hormone Somavaratan (VRS-317) in Children with Growth Hormone Deficiency
The VISTA Study: Versartis Long-Term Safety Study of Somavaratan
Summary
|
|
EudraCT number |
2016-002780-34 |
Trial protocol |
SE BE PL |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
27 Jan 2022
|
First version publication date |
27 Jan 2022
|
Other versions |
|
Summary report(s) |
13VR3 Abbreviated CSR |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.